Constipation on Zepbound (tirzepatide): Incidence, Severity, and Realistic Expectations
How common is constipation on Zepbound? A clinical breakdown of trial-reported rates, severity grades, risk factors, timeline, and practical management steps.
15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

Showing 15 of 15 clinical reviews.
How common is constipation on Zepbound? A clinical breakdown of trial-reported rates, severity grades, risk factors, timeline, and practical management steps.
A week-by-week breakdown of when constipation starts, peaks, and typically resolves on Zepbound (tirzepatide), with trial data and management strategies for each phase.
Specific dietary, hydration, meal-timing, and supplement strategies to reduce constipation on Zepbound (tirzepatide), based on trial data and GI management evidence.
A clinical protocol for assessing, treating, and escalating constipation caused by Zepbound (tirzepatide), with specific interventions at each stage and clear criteria for when to change course.
OTC and prescription options for treating constipation caused by Zepbound (tirzepatide), with first-line and second-line agents, dose ranges, and drug interactions to watch.
Evidence-based supplements for managing constipation caused by Zepbound (tirzepatide), including psyllium, magnesium, and probiotics, with dosing, trial data, and clinical guidance.
Clinical protocols for adjusting Zepbound dose titration to manage constipation, including slowing schedules, pausing, stepping down, and microdosing strategies.
Clinical thresholds for discontinuing Zepbound due to constipation: severity criteria, quality-of-life impact, lab markers, timeline benchmarks, and alternative medications.
A clinical breakdown of the GLP-1 and GIP receptor mechanisms behind tirzepatide-induced constipation, including trial data from SURMOUNT, management strategies, and when to contact your prescriber.
Clinical explanation of how Zepbound (tirzepatide) slows gut motility through GLP-1 and GIP receptor activation, causing constipation in up to 7% of patients.
Evidence-based dietary strategies to relieve constipation caused by Zepbound (tirzepatide), including fiber timing, hydration targets, and foods to prioritize or avoid during GLP-1 therapy.
Learn when constipation from Zepbound (tirzepatide) requires medical attention, why GLP-1/GIP agonists slow gut motility, and how to manage symptoms safely.
A clinical severity grading rubric for constipation caused by Zepbound (tirzepatide), including CTCAE-based grading, management strategies by grade, mechanism of action, and when to seek medical attention.
Persistent constipation on Zepbound (tirzepatide) affects up to 1 in 4 patients. Learn why it happens, evidence-based treatments, and when to contact your prescriber.
Evidence-based alternatives to Zepbound (tirzepatide) for patients who experience constipation, including management strategies, lower-risk GLP-1 options, and non-incretin weight-loss medications.